Newsletter | March 30, 2026

03.30.26 -- Unlocking The Therapeutic Power Of Fibroblasts With Pete O'Heeron And Hamid Khoja, Ph.D.

FEATURED ARTICLE

Unlocking The Therapeutic Power Of Fibroblasts With Pete O'Heeron And Hamid Khoja, Ph.D.

 In this episode of “Better Biopharma,” host Tyler Menichiello is joined by FibroBiologics’ CEO and Founder, Pete O’Heeron, and chief scientific officer, Hamid Khoja, Ph.D.

INDUSTRY INSIGHTS

Advancing ADCs With Expertise In Payloads And Linkers

Power your ADC program forward with seamless containment, high‑potency know‑how, advanced chromatography, and optimized linker‑payload workflows for faster, more dependable commercial success.

What Top Biotechs Know: The CRO Advantage That Drives Trial Success

For early-stage biotech companies, the road from discovery to market is fraught with challenges, and in this environment, strategic partnerships with CROs have become a cornerstone of clinical success.

Eastern NC Biomanufacturing Region Reports Strong Growth

Eastern North Carolina is rapidly becoming a biomanufacturing powerhouse, capturing most of the state’s recent life sciences investment and job growth while expanding training programs.

Automation’s Role In Ending Drug Quality Blind Spots

Automated visual inspection (AVI) combines robotics, precision imaging, and sophisticated defect-recognition software to provide a scalable solution for expanding pipelines and rises in production volumes.

Turning Innovation Into Execution In CNS Trials

SCOPE 2026 experts called for practical planning, iterative testing, and real‑world workflows in mental health research, highlighting mock visits, expanded roles, engagement, and psychedelic safety.

Flexibility And Capability In Pre-Filled Syringes: The Future Of PFS

Explore the benefits of PFS for delivering biologics and vaccines, the surge in demand driven by SARS‑CoV‑2, and why partnering with a flexible CDMO is critical for meeting evolving market needs.

The Overlooked Safety Step Clinical Trials Can’t Ignore

Reliable trials start with consistent, vigilant safety data collection. Learn how a strong safety culture sharpens oversight, supports faster risk detection, and protects patients at every stage.